Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal (Q38969462)

8 September 2017

title

Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal (English)

1 reference

8 September 2017

0 references

1 reference

Guilherme Gonçalves

1

0 references

João Rodrigo Mesquita

object named as

João Rodrigo Mesquita

4

0 references

Carla Nunes

object named as

Carla Nunes

Maria São José Nascimento

3

0 references

object named as

Maria São José Nascimento

5

0 references

author name string

João Frade

2

1 reference

8 September 2017

language of work or name

English

0 references

publication date

27 August 2015

1 reference

8 September 2017

1 reference

8 September 2017

volume

33

1 reference

8 September 2017

issue

39

1 reference

8 September 2017

page(s)

5057-5063

1 reference

Measles elimination: progress, challenges and implications for rubella control

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Editorial commentary: A rare event: a measles outbreak in a population with high 2-dose measles vaccine coverage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Field effectiveness of live attenuated measles-containing vaccines: a review of published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Long-term persistence of antibodies after one or two doses of MMR-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Levels of rubella antibody among vaccinated and unvaccinated Portuguese mothers and their newborns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Single point quantification of antibody by ELISA without need of a reference curve.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Herd immunity: recent uses in vaccine assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Potential impacts of schedule changes, waning immunity and vaccine uptake on measles elimination in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.057

10.1016/J.VACCINE.2015.08.057

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference